<DOC>
	<DOCNO>NCT00496340</DOCNO>
	<brief_summary>The objective trial determine whether regimen pentostatin busulfan ( IV ) facilitate engraftment human leukocyte antigen ( HLA ) partially compatible sibling unrelated donor transplant use CD4+ laboratory-guided immunosuppression among 41 transplant patient meet inclusion criterion .</brief_summary>
	<brief_title>Phase II Trial Pentostatin Targeted Busulfan</brief_title>
	<detailed_description>Pentostatin ( deoxycoformycin ) purine analogue currently indicate treatment chemo-naïve interferon-refractory hairy cell leukemia . Pentostatin represent ideal agent condition recipient allogeneic hematopoietic cell transplantation ( HCT ) due significant effect lymphocytes relatively reduced myelosuppression compare purine analogue . It potent inhibitor enzyme adenosine deaminase ( ADA ) whose activity generally pronounce T lymphocyte compare B counterpart . Also , pentostatin show , though immunomodulatory effect active patient steroid-refractory acute graft versus host disease ( aGVHD ) . Pentostatin-based regimen study condition strategy patient undergo allogeneic stem cell transplantation . Chan et al . evaluate 18 myelodysplastic syndrome ( MDS ) patient ineligible standard allogeneic transplantation . In series , patient receive condition preparative regimen photopheresis day -7 -6 , pentostatin 4 mg/m^2 continuous infusion day -5 -4 , total body irradiation 600 centigray ( cGy ) 3 fraction day -3 -2 , follow allogeneic stem cell infusion 6/6 5/6 HLA-matched related donor 6/6 HLA-matched unrelated donor . Sixteen 18 ( 89 % ) patient develop full donor chimerism , day +100 transplant-related mortality ( TRM ) . Grade 2 4 aGVHD extensive chronic graft versus host disease ( GVHD ) develop 19 % 18 % patient , respectively . Disease relapse occur 2 patient . At median follow-up 14 month ( range , 1-35 month ) , 1-year failure-free overall survival 64 % 65 % , respectively . These finding clearly suggest Pentostatin-based regimen capable achieve successful donor engraftment durable disease-remission significantly lesser transplant toxicity grade 2 4 acute GVHD . Pavletic et al. , demonstrate Pentostatin induces significant lympho-depleting effect promise safety , support use condition regimen non-myeloablative strategy hematopoietic cell infusion early 7 day initiation Pentostatin . Busulfan available primarily oral formulation recently . The oral drug variable bioavailability link erratic gastrointestinal absorption patient patient . In phase I trial , Andersson et al evaluate IV Bu formulation use dimethylacetamide PEG400 solvent . This formulation currently market USA ( Busulfex ESP Pharma ) . Fifteen patient advance hematologic malignancy treat BU every 6 hour total 16 dos follow cyclophosphamide ( CY ) 60mg/kg 2 dos hematopoietic cell transplant . The first BU dose give IV . The start IV dose 0.08mg/kg escalate 0.2 , 0.4 , finally 0.8mg/kg cohort 3 patient . Six hour start IV BU infusion , patient begin receive oral BU 1mg/kg every 6 hour 15 dos . Pharmacokinetic profile obtain determine equivalent exposure IV BU oral BU dose 1mg/kg . It note toxicity profile rate engraftment similar oral drug ( i.e. , additional toxicity find attributable solvent ) . An IV dose 0.8mg/kg give equivalent AUC ( less variability ) oral dose 1mg/kg mean AUC 1189 micrometer ( uM ) -min ( range 964-1547uM-min ; 24h DIE 4756uM-min [ range 3856-6188uM-min ] ) . Thus , 0.8mg/kg chosen investigator dose proceed phase II testing . A subsequent phase II multicenter trial 61 patient variety hematologic malignancy use 0.8mg/kg every 6 hour x 16 dos IV BU 120mg/kg CY prior hematopoietic stem cell transplant . Pharmacokinetic analysis also do . Once , show toxicity outcome data similar publish oral BU . There patient seizure . Lung toxicity occur two patient , one diffuse alveolar hemorrhage ( DAH ) one interstitial pneumonitis ( IP ) ; latter patient history lung irradiation . Grade 1-2 nausea emesis occur 43 % grade 3 7 % . Mucositis grade 2 44 % , Grade 3 26 % last median 6 day . There five ( 8 % ) case veno-occlusive disease ( VOD ) , fatal two ( 3 % ) . Treatment related mortality 100 day 9.8 % . The AUC &lt; 1500 uM-min ( 24h DIE &lt; 6000uM-min ) 55 % ; 86 % patient maintain AUC 800 1500uM-min ( 24h DIE 3200-6000uM-min ) . The AUC dose 1 dose 9 similar indicate consistent dose-to-dose behavior . The author conclude IV BU set well tolerate demonstrate excellent antitumor efficacy , likely result predictable pharmacokinetics . Based study , IV administration become preferred route BU give high dose transplant setting . Fernandez , et al . evaluate use IV Bu ( Busulfex® ESP Pharma ) either daily twice daily dose schedule give part BUCY regimen ( BU : 3.2 mg/kg CY 120mg/kg ) prior transplant . In dose schedule , little variability dose-to-dose level pharmacokinetics first dose could predict data subsequent dos . In twice-daily group , AUC 3390uM-min ( 2400- 4678uM-min ; 24h DIE 6780uM-min [ 4800-9356uM-min ] ) daily group AUC 5561uM-min ( 4412 - 7368uM-min ) . The pharmacokinetic profile ( AUC , CL , Cmax 1/2 ) similar dose dose . In twelve patient study , follow grade 3 toxicity report : mucositis , anorexia , infection , epistaxis hyperglycemia . Two patient die : one sepsis presume fungal infection one sudden cardiac death . One patient develop mild , reversible VOD . Daily dose IV Bu result similar outcome toxicity profile compare oral dose ease delivering target exposure BU . The importance able target BU exposure illustrate discussion report correlate BU pharmacokinetic parameter toxicity efficacy . Thus , utilize daily IV dose , target prespecified level , BU therapy optimize limit toxicity maximize efficacy . To see AUC IV Bu correlate adverse effect , Andersson colleague treat 36 chronic myelogenous leukemia ( CML ) patient either fix adjust dose BuCy . The first 25 patient give fix dose Bu 0.8mg/kg every 6 hour . In subsequent 12 patient , dos adjust achieve AUC 1250uM-min ( 24h DIE 5000uM-min ) . At steady state , population median AUC 1265uM-min ( range , 816-1905uM-min [ 24h DIE 5056uM-min ; 3264-7620uM-min ] ) . They find probability develop gastrointestinal toxicity , hepatotoxicity , mucositis , acute GVHD increase increase AUC . The 26 patient within AUC 950 - 1520uM-min ( 24h DIE 3800-6080uM-min ) decrease incidence death compare 10 patient outside range . There case hepatic veno-occlusive disease seizure . These small number indicate trend towards achieve optimal systemic exposure deliver individualized dos suggestion `` therapeutic window '' Bu setting . The importance able target BU exposure illustrate discussion report correlate Bu pharmacokinetic parameter toxicity efficacy . Thus , utilize daily IV dose , target prespecified level , Bu therapy optimize limit toxicity maximize efficacy . Rituximab anti-CD20 human-mouse chimeric monoclonal antibody indicate treatment relapsed refractory , low-grade follicular , CD20-positive , B-cell NHL . The use rituximab , monotherapy , result significant response duration response patient indolent non-Hodgkin 's lymphoma ( NHL ) ; efficacy improve even use combination chemotherapy indolent aggressive NHL . Responses rituximab treatment vary histologic subtype NHL . In patient low-grade follicular lymphoma , response rate approximately 70 % 75 % first-line therapy . On hand , patient diffuse B-cell large-cell lymphoma ( DBLCL ) , single-agent rituximab result response rate 30 % 40 % report . Rituximab significantly increase response rate use combination cyclophosphamide , doxorubicin , vincristine , prednisone . CD20 express hematopoietic stem cell , therefore , hypothesize treatment rituximab safe would inhibit engraftment produce early progenitor . Treatment rituximab may successfully eliminate minimal residual disease , delay prevent disease relapse potentially extend duration survival CD20+ express malignancy .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Recipients : Age : great 18 year age , young parental consent . HLA A , B , C , DRB1 , DQB1 , 10/10 9/10 allele sequence match related donor unrelated donor available Histologically confirm diagnosis pathologic review . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , Karnofsky performance status great 70 Organ function : 1 . Pulmonary : diffusing capacity lung carbon monoxide ( DLCO ) &gt; /= 50 % 2 . Cardiac : leave ventricular ejection fraction &gt; /= 50 % 3 . Renal : creatinine clearance ( measure calculate ) equal great 50 ml/min ( time pentostatin administer ) 4 . Hepatic : total bilirubin less equal 2mg/dL , ( Gilbert syndrome increase indirect bilirubin allow ) ; serum transaminase less two time institutional upper limit normal ( &lt; 2 x ULN ) . Donors : Capable receive Granulocyte ColonyStimulating Factor ( GCSF ) undergo apheresis Age &gt; 18 Signed inform consent form accordance institutional National Donor Marrow Program ( NMDP ) policy Recipients : Pregnant lactate woman HIV seropositive , confirm nucleic acid test ( NAT ) Active central nervous system ( CNS ) malignancy Active infection Unfavorable psychosocial evaluation history poor compliance prescribe medical care . Current use metronidazole acetaminophen ; patient must discontinue use agent least 7 day prior start Busulfex administration Prior allogeneic HCT ( patient receive prior autologous HCT allow ) Lack capable caregiver . Presence follow comorbid condition 1 . History recent myocardial infarction within 30 day 2 . Congestive heart failure ( NY class III , IV symptomatically uncontrolled ) 3 . Peripheral vascular disease ( include intermittent claudication history bypass arterial insufficiency ) 4 . Untreated thoracic abdominal aneurysm ( 6 cm ) 5 . History cerebrovascular accident include transient ischemic attack within 30 day 6 . Dementia 7 . History recent gastrointestinal bleeding ( within 30 day ) 8 . Connective tissue/rheumatologic disorder 9 . Hemiplegia/paraplegia 10 . History solid tumor exclude skin cervical carcinoma curative resection . Patients prior solid tumor ( ) remission 5 year allow casebycase basis Donors : Pregnant lactate woman HIV seropositive , confirm NAT Human T lymphotropic virus ( HTLV ) I/II seropositive Hepatitis B C seropositive Donors uncontrolled bacterial , viral , fungal parasitic infection . Donors know hypersensitivity recombinant human GCSF E. coliderived product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pentostatin</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
</DOC>